Leukogene Therapeutics has received orphan drug designation from the US FDA for M2T-CD33 (LTI-214), its immunotherapy candidate targeting AML.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback